88 related articles for article (PubMed ID: 24375227)
1. Polymorphic transformation of antibiotic clarithromycin under acidic condition.
Noguchi S; Takiyama K; Fujiki S; Iwao Y; Miura K; Itai S
J Pharm Sci; 2014 Feb; 103(2):580-6. PubMed ID: 24375227
[TBL] [Abstract][Full Text] [Related]
2. Stabilization mechanism of clarithromycin tablets under gastric pH conditions.
Fujiki S; Iwao Y; Kobayashi M; Miyagishima A; Itai S
Chem Pharm Bull (Tokyo); 2011; 59(5):553-8. PubMed ID: 21532191
[TBL] [Abstract][Full Text] [Related]
3. Suppressed Release of Clarithromycin from Tablets by Crystalline Phase Transition of Metastable Polymorph Form I.
Fujiki S; Watanabe N; Iwao Y; Noguchi S; Mizoguchi M; Iwamura T; Itai S
J Pharm Sci; 2015 Aug; 104(8):2641-4. PubMed ID: 26053058
[TBL] [Abstract][Full Text] [Related]
4. Effect of gel formation on the dissolution behavior of clarithromycin tablets.
Inukai K; Takiyama K; Noguchi S; Iwao Y; Itai S
Int J Pharm; 2017 Apr; 521(1-2):33-39. PubMed ID: 28196716
[TBL] [Abstract][Full Text] [Related]
5. Modulation of microenvironmental pH and utilization of alkalizers in crystalline solid dispersion for enhanced solubility and stability of clarithromicin.
Park JB; Park YJ; Kang CY; Lee BJ
Arch Pharm Res; 2015; 38(5):839-48. PubMed ID: 25213008
[TBL] [Abstract][Full Text] [Related]
6. Clarithromycin form I determined by synchrotron X-ray powder diffraction.
Noguchi S; Miura K; Fujiki S; Iwao Y; Itai S
Acta Crystallogr C; 2012 Feb; 68(Pt 2):o41-4. PubMed ID: 22307251
[TBL] [Abstract][Full Text] [Related]
7. Free transport of water and CO2 in nonporous hydrophobic clarithromycin form II crystals.
Tian J; Thallapally PK; Dalgarno SJ; Atwood JL
J Am Chem Soc; 2009 Sep; 131(37):13216-7. PubMed ID: 19715295
[TBL] [Abstract][Full Text] [Related]
8. [Development of Novel Functional Formulations Based on Pharmaceutical Technologies].
Itai S
Yakugaku Zasshi; 2019; 139(3):419-435. PubMed ID: 30828022
[TBL] [Abstract][Full Text] [Related]
9. Optimum heat treatment conditions for masking the bitterness of the clarithromycin wax matrix.
Yajima T; Itai S; Takeuchi H; Kawashima Y
Chem Pharm Bull (Tokyo); 2003 Nov; 51(11):1223-6. PubMed ID: 14600362
[TBL] [Abstract][Full Text] [Related]
10. Physicochemical properties of amorphous clarithromycin obtained by grinding and spray drying.
Yonemochi E; Kitahara S; Maeda S; Yamamura S; Oguchi T; Yamamoto K
Eur J Pharm Sci; 1999 Mar; 7(4):331-8. PubMed ID: 9971917
[TBL] [Abstract][Full Text] [Related]
11. pH-sensitive hydrogels based on semi-interpenetrating network (semi-IPN) of chitosan and polyvinyl pyrrolidone for clarithromycin release.
Vaghani SS; Patel MM
Drug Dev Ind Pharm; 2011 Oct; 37(10):1160-9. PubMed ID: 21417603
[TBL] [Abstract][Full Text] [Related]
12. Physicochemical properties and stability in the acidic solution of a new macrolide antibiotic, clarithromycin, in comparison with erythromycin.
Nakagawa Y; Itai S; Yoshida T; Nagai T
Chem Pharm Bull (Tokyo); 1992 Mar; 40(3):725-8. PubMed ID: 1535292
[TBL] [Abstract][Full Text] [Related]
13. Chitosan-carboxymethylcellulose interpolymer complexes for gastric-specific delivery of clarithromycin.
Gómez-Burgaz M; García-Ochoa B; Torrado-Santiago S
Int J Pharm; 2008 Jul; 359(1-2):135-43. PubMed ID: 18479852
[TBL] [Abstract][Full Text] [Related]
14. Phase transitions of antibiotic clarithromycin forms I, IV and new form VII crystals.
Ito M; Shiba R; Watanabe M; Iwao Y; Itai S; Noguchi S
Int J Pharm; 2018 Aug; 547(1-2):258-264. PubMed ID: 29864514
[TBL] [Abstract][Full Text] [Related]
15. Polymorphism of clarithromycin.
Sohn YT; Rhee JK; Im WB
Arch Pharm Res; 2000 Aug; 23(4):381-4. PubMed ID: 10976587
[TBL] [Abstract][Full Text] [Related]
16. Polymorphism in sulfadimidine/4-aminosalicylic acid cocrystals: solid-state characterization and physicochemical properties.
Grossjohann C; Serrano DR; Paluch KJ; O'Connell P; Vella-Zarb L; Manesiotis P; Mccabe T; Tajber L; Corrigan OI; Healy AM
J Pharm Sci; 2015 Apr; 104(4):1385-98. PubMed ID: 25605031
[TBL] [Abstract][Full Text] [Related]
17. Dissolution enhancement and in vitro performance of clarithromycin nanocrystals produced by precipitation-lyophilization-homogenization method.
Morakul B; Suksiriworapong J; Chomnawang MT; Langguth P; Junyaprasert VB
Eur J Pharm Biopharm; 2014 Nov; 88(3):886-96. PubMed ID: 25201298
[TBL] [Abstract][Full Text] [Related]
18. Saturated fatty acids and fatty acid esters promote the polymorphic transition of clarithromycin metastable form I crystal.
Watanabe M; Mizoguchi M; Aoki H; Iwao Y; Noguchi S; Itai S
Int J Pharm; 2016 Oct; 512(1):108-117. PubMed ID: 27553780
[TBL] [Abstract][Full Text] [Related]
19. Interplay of degradation, dissolution and stabilization of clarithromycin and its amorphous solid dispersions.
Pereira JM; Mejia-Ariza R; Ilevbare GA; McGettigan HE; Sriranganathan N; Taylor LS; Davis RM; Edgar KJ
Mol Pharm; 2013 Dec; 10(12):4640-53. PubMed ID: 24116899
[TBL] [Abstract][Full Text] [Related]
20. Investigation into physical-chemical variables affecting the manufacture and dissolution of wet-milled clarithromycin nanoparticles.
Shahbazi Niaz M; Traini D; Young PM; Ghadiri M; Rohanizadeh R
Pharm Dev Technol; 2014 Dec; 19(8):911-21. PubMed ID: 24093825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
